What is Neurasthenia?
Neurasthenia is a neurological condition primarily characterized by persistent physical and mental fatigue, often aggravated by exertion. Patients commonly experience accompanying symptoms such as depression, anxiety, headaches, dizziness, and other signs of autonomic dysfunction. While fatigue predominates, the disorder overlaps with mood disturbances but is distinguished by its emphasis on exhaustion rather than primary affective symptoms. Historically recognized as "nervous weakness," it was once prevalent in Western medicine but is now largely deprecated in modern classifications like DSM and ICD-11, except in certain cultural contexts (e.g., shenjing shuairuo in Chinese psychiatry). Treatment focuses on symptom management, as no specific cure exists, involving antidepressants (with limited efficacy), cognitive behavioral therapy (CBT), graded exercise therapy, lifestyle modifications, and supportive care to alleviate fatigue and associated complaints.
Market Overview
According to Data Bridge Market Research, the global neurasthenia treatment market was valued at USD 100 million in 2022 and is projected to reach USD 158.19 million by 2030, growing at a CAGR of 5.90% during the forecast period of 2023–2030. This steady growth reflects increasing recognition of chronic fatigue-related conditions, rising prevalence of stress-induced disorders, and ongoing R&D into rehabilitative therapies, despite the condition's rarity and diagnostic challenges.
Market Segmentation
The market is segmented as follows:
- By Symptoms: Depression, Anxiety, Others.
- By Clinical Feature: Physical Fatigue, Mental Fatigue.
- By End-Users: Hospitals, Homecare, Specialty Centres, Others.
- By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
Hospitals and specialty centres dominate end-user segments due to the need for multidisciplinary management, while online and retail pharmacies facilitate access to supportive medications.
Key Market Drivers
- Rising prevalence of fatigue, depression, and anxiety disorders, influenced by modern lifestyles, socioeconomic pressures, and high-stress environments.
- Increasing R&D activities focused on innovative therapies, emphasizing psychological rehabilitation over purely pharmacological approaches.
- Growing awareness and diagnosis rates, particularly in populations with high disposable incomes and access to mental health services.
Restraints and Challenges
Opportunities
- Expansion of rehabilitative approaches like CBT and graded exercise therapy, supported by evidence of efficacy.
- Rising global rates of depression and related disorders, creating demand for multifaceted management strategies.
- Growth in accessible distribution channels, such as online pharmacies, enhancing treatment adherence.
Regional Insights
- Asia-Pacific dominates the market, driven by higher reported prevalence of fatigue and depression, cultural recognition of neurasthenia-like conditions, and expanding healthcare access.
- North America exhibits strong growth potential, benefiting from advanced healthcare infrastructure, affordability, and heightened awareness.
Other regions show varied adoption influenced by local diagnostic practices and mental health priorities.
Major Market Players
Key companies include:
- Johnson & Johnson Services, Inc.
- COOPERSURGICAL, INC
- MEDGYN PRODUCTS, INC
- Thomas Medical
- Smiths Group plc
- Panpac Medical Corp
- Personal Medical Corp.
- Boston Scientific Corporation
- Coloplast Pvt. Ltd
- Cook
- Integra LifeSciences
- medesign IC GmbH
- Medtronic
These players invest in R&D and strategic initiatives to address symptom management needs.
Conclusion
The global neurasthenia treatment market is poised for moderate growth through 2030, supported by increasing mental health burdens and rehabilitative therapy advancements. With a projected value of USD 158.19 million, Asia-Pacific leads due to prevalence factors, while North America advances rapidly. Opportunities in psychological interventions and awareness will counter limited treatment efficacy, improving management of fatigue-dominant disorders worldwide.
This summary is based on publicly available insights from the Data Bridge Market Research report overview as of late 2025. For detailed quantitative forecasts, financials, and custom analysis, refer to the full report at the original source.
Browse More Reports:
Asia-Pacific Medical Device Reprocessing Market
Europe Busbar Market
Middle East and Africa Busbar Market
Asia-Pacific Busbar Market
North America Busbar Market
North America Anti-Friction Coatings Market
Europe Anti-Friction Coatings Market
Asia-Pacific Anti-Friction Coatings Market
Middle East and Africa Anti-Friction Coatings Market
North America Automated Liquid Handling Market
Asia-Pacific Automated Liquid Handling Market
Europe Automated Liquid Handling Market
Asia-Pacific Digital Forensics Market
Europe Functional Mushroom Market
Asia-Pacific Functional Mushroom Market
About Data Bridge Market Research:
An absolute way to forecast what the future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com
About
Términos
Privacidad
Contact
Invest
Thai
English
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian